Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802781
  • Drug Pipelines
  • 36 pages
  • Global Markets Direct
1 of 5
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1)
- The report reviews Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Overview

Therapeutics Development

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Stage of Development

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Therapy Area

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Indication

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Products Glance

Early Stage Products

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Companies

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Universities/Institutes

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Drug Profiles

AN-3485 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-13148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Rho-Associated Kinase I for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Dormant Projects

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Discontinued Products

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Featured News & Press Releases

Jun 18, 2013: Moffitt Cancer Center Announces Strategic Partnership with Advinus Therapeutics

Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types

Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types

Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says

Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 36List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Anacor Pharmaceuticals, Inc., H1 2016

Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 30List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively.

The author's latest report Rho-Associated Protein Kinase 1 - Pipeline Review, H1 2016, outlays comprehensive information on the Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Anacor Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll